LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

Emergent BioSolutions Inc

Closed

SectorHealthcare

10.09 -1.75

Overview

Share price change

24h

Current

Min

10.07

Max

10.21

Key metrics

By Trading Economics

Income

63M

51M

Sales

90M

231M

P/E

Sector Avg

8.326

105.69

Profit margin

22.155

Employees

900

EBITDA

95M

96M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+48.37% upside

Market Stats

By TradingEconomics

Market Cap

58M

577M

Previous open

11.84

Previous close

10.09

News Sentiment

By Acuity

50%

50%

160 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Emergent BioSolutions Inc Chart

Past performance is not a reliable indicator of future results.

Related News

14 Nov 2025, 17:45 UTC

Earnings
Major Market Movers

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 Nov 2025, 17:31 UTC

Earnings
Major Market Movers

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14 Nov 2025, 16:15 UTC

Major Market Movers

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

15 Nov 2025, 09:20 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

15 Nov 2025, 09:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

15 Nov 2025, 00:08 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14 Nov 2025, 23:56 UTC

Acquisitions, Mergers, Takeovers

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 Nov 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 Nov 2025, 22:35 UTC

Earnings
Acquisitions, Mergers, Takeovers

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 Nov 2025, 22:32 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 Nov 2025, 22:29 UTC

Earnings

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 Nov 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 Nov 2025, 21:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

14 Nov 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 Nov 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 Nov 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 Nov 2025, 20:17 UTC

Acquisitions, Mergers, Takeovers

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 Nov 2025, 19:29 UTC

Market Talk
Earnings

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 Nov 2025, 18:44 UTC

Market Talk
Earnings

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 Nov 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14 Nov 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 Nov 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 Nov 2025, 17:20 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

14 Nov 2025, 17:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

14 Nov 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14 Nov 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14 Nov 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14 Nov 2025, 16:38 UTC

Market Talk

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14 Nov 2025, 16:30 UTC

Acquisitions, Mergers, Takeovers

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14 Nov 2025, 16:28 UTC

Market Talk

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

Peer Comparison

Price change

Emergent BioSolutions Inc Forecast

Price Target

By TipRanks

48.37% upside

12 Months Forecast

Average 15 USD  48.37%

High 15 USD

Low 15 USD

Based on 1 Wall Street analysts offering 12 month price targets forEmergent BioSolutions Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

4.95 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

160 / 374 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
help-icon Live chat